Tampa, FL, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that Joshua (Josh) Mann recently joined the company as Vice President, Cancer Information Data Trust (CIDT) Program. In this capacity, he will be responsible for aligning the CIDT business strategy with systems design and data flow, spanning data collection, organization and management, as well as data analysis and visualization.
A “big data” initiative, the CIDT is being built by Inspirata to deliver insightful, longitudinal information about cancer patients’ disease types, treatments and outcomes through a variety of end-user focused portals and applications. Through these interfaces, users—such as clinicians, administrators, researchers, bio pharma scientists, patients and caregivers—will be able to access structured, searchable and mineable cancer data, including diagnostic images from pathology, radiology and endoscopy; molecular tests; clinical notes; treatments; and outcomes. This information can then be used to offer insights into prognosis, treatment options, costs and quality of care. Beyond patient care, the CIDT will be a valuable resource for drug discovery, treatment options, education, as well as cancer incidence and survival data for epidemiological studies.
“Josh is uniquely qualified to lead the construction of this very important big data project,” says Inspirata CEO Satish Sanan. “The CIDT has been the centerpiece of Inspirata’s product vision from the very beginning with its distinguishing feature being pathology and molecular data along with the associated whole slide images and other diagnostic images, many of which are not included in other cancer-related big data initiatives. Josh understands the value of image-anchored cancer data and will bring his extensive experience in clinical and analytical systems to help us build the preeminent source for cancer data.”
Mann brings more than two decades of experience in Health Information Technology (HIT) to his new role at Inspirata. Prior to his work in this space, he developed software and led multi-million dollar projects for companies such as Microsoft, Nestle, Johnson & Johnson, to name a few. In 2007, Mann joined a 14-hospital health system where he worked with a network of community cancer centers and focused in on the National Cancer Institute’s (NCI) National Community Cancer Centers Program (NCCCP) and Cancer BioInformatics Grid (caBIG®) initiatives.
In 2011, Mann joined the American Society of Clinical Oncology (ASCO) as the architect for CancerLinQ®, which is widely considered one of ASCO’s most ambitious initiatives designed to help practicing physicians distill massive volumes of oncology patient data into meaningful information that supports research as well as the delivery of high-quality, high-value care at the bedside. He left ASCO in 2014 as Director of Oncology Technology Solutions and Acting CTO for the CancerLinQ, a subsidiary of ASCO, having successfully developed the CancerLinQ prototype, along with the corresponding business model and plans.
In 2014, Mann co-founded SHARE for Cures, a non-profit organization that seeks to empower the patient community to use their individual health data to advance medical research and save lives. SHARE For Cures was featured as part of the White House Cancer Moonshot Initiative in 2016. Mann remains on the board of directors of SHARE For Cures.
Immediately prior to joining Inspirata, Mann also ran a consulting firm through which he served as a Consulting CIO to Guardian Research Network, a network of community hospitals that came together to accelerate disease research and clinical trial enrollment; and provided consulting services to a variety of organizations involved with clinical care and research, including Kaiser Permanente, where he and his team oversaw the Mid-Atlantic Region’s Clinical and Business Intelligence development activities. Since 2006, Mann has had more than 50 papers published on the topics of improving HIT and the quality of patient care and outcomes, as well as on population health and big data in healthcare.
About Inspirata, Inc.
Inspirata®, Inc. offers the most comprehensive cancer diagnostics workflow solution available for precision diagnosis today. The solution, which employs a unique “solution-as-a-service” business and delivery model, accelerates anatomic and molecular pathology workflows and facilitates whole slide imaging and image analytics, prognostic and predictive assays, remote consultations and tumor boards. This comprehensive solution includes an Enterprise Service Bus (ESB) to help to solve interoperability issues and a Natural Language Processing Engine (NLP) for structuring data. Inspirata amalgamates this structured data into a central multi-institutional and multi-modal big data cancer repository for clinical, research and educational purposes. Its use will extend to physicians, patients, researchers and pharma among others. This comprehensive solution facilitates a modern precision diagnosis to build a strong foundation for precision medicine. For more information, please visit www.inspirata.com or contact email@example.com.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/10f15566-1aa4-48e9-aa2e-19103e14f7b6
Marjorie Bulone Inspirata, Inc. 813-570-8905 firstname.lastname@example.org